Quantum Biopharma Files $700M Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 26 Nov 25
Source: Globenewswire
Quantum Biopharma Ltd has filed a $700 million lawsuit against CIBC and RBC, alleging market manipulation that could damage its reputation and stock price.
The lawsuit has garnered media attention, with CTV News planning a three-part series to raise awareness about market manipulation, potentially affecting investor confidence.
CEO Zeeshan Saeed emphasized the importance of protecting retail investors and expressed hope that this legal action will enhance the company's image and attract more interest in its R&D projects.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
